cyc 202 and Leukemia
cyc 202 has been researched along with Leukemia in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Andera, L; Beranova, L; Bohmova, M; Gasova, Z; Ivanek, R; Klanova, M; Klener, P; Koc, M; Ludvikova, Z; Molinsky, J; Necas, E; Strnad, M; Trneny, M; Zivny, J | 1 |
| Conrad, D; Dai, Y; Dent, P; Grant, S; Krystal, G; Rahmani, M; Yu, C | 1 |
| Almenara, JA; Atadja, P; Craig, R; Dent, P; Grant, S; Maggio, SC; Rosato, RR; Vrana, J | 1 |
| Chen, S; Dai, Y; Dent, P; Grant, S; Harada, H | 1 |
Other Studies
4 other study(ies) available for cyc 202 and Leukemia
| Article | Year |
|---|---|
Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line, Tumor; Cytotoxicity, Immunologic; Death Domain Receptor Signaling Adaptor Proteins; Fas Ligand Protein; Humans; Leukemia; Lymphoma; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Tumor Burden; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2013 |
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Topics: 2-Aminopurine; Antineoplastic Agents; Apoptosis; Chromones; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Flavonoids; Humans; Leukemia; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Roscovitine; Tumor Cells, Cultured | 2003 |
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cytochromes c; Cytosol; Down-Regulation; Enzyme Inhibitors; Flow Cytometry; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Jurkat Cells; Leukemia; Membrane Potentials; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Roscovitine; Time Factors; U937 Cells; X-Linked Inhibitor of Apoptosis Protein | 2005 |
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Biphenyl Compounds; Cyclin-Dependent Kinases; Down-Regulation; Drug Synergism; HL-60 Cells; Humans; Jurkat Cells; Leukemia; Mice; Mice, Knockout; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; RNA Interference; Roscovitine; Sulfonamides; U937 Cells | 2007 |